Related Articles
00 / 00
Important announcement concerning Temple Health and Keystone First. Our provider agreement with Keystone First, is scheduled to end on July 31st. Learn about your options to continue receiving care at Temple Health.
Request an Appointment
Assistant Professor, Department of Bone Marrow Transplant and Cellular Therapies
Lymphoma, Leukemia, Myeloma
Stem cell transplant, cellular therapies
After completing my fellowship at Fox Chase, I’m delighted to continue my career here, joining the collaborative team of outstanding clinicians and researchers, dedicated to providing best care to our patients. My philosophy of care is to treat every patient like family. This means educating them fully about their treatment options and helping them make the right decision for the best possible outcome. A diagnosis of cancer can be challenging to deal with, but with a caring, experienced team behind a patient, the journey can feel less stressful.
Pooja Ghatalia, Chad H. Smith, Arthur Winer, Jiangtao Gou , Lesli A. Kiedrowski, Michael Slifker, Patricia D. Saltzberg, Nicole Bubes, Fern M. Anari, Vineela Kasireddy, Asya Varshavsky , Yang Liu, Eric A. Ross, Wafik S. El-Deiry Clinical Utilization Pattern of Liquid Biopsies (LB) to Detect Actionable Driver Mutations, Guide Treatment Decisions and Monitor Disease Burden During Treatment of 33 Metastatic Colorectal Cancer (mCRC) Patients (pts) at a Fox Chase Cancer Center GI Oncology Subspecialty Clinic. Frontiers in Oncology 2019.
Shastri, A., Schinke, C., Varshavsky Yanovsky, A., Bhagat, T. D., Giricz, O.,Barreyro, L., Boultwood, J., Pellagati, A., Yu, Y., Brown, J. R., Frank, D. A.,Das, B., Kambhampati, S., Will, B., Steidl, U., & Verma, A Targeting of MDS and AML Stem Cells Via Inhibition of STAT3 By Pyrimethamine. Blood 2014, 124(21).
Kigel B, Rabinowicz N, Varshavsky A, Kessler O, Neufeld G (2011) Plexin-A4 promotes tumor progression and tumor angiogenesis by enhancement of VEGF and bFGF signaling. Blood. 2011 Aug 10.
Varshavsky A, Kessler O, Abramovitch S, Kigel B, Zaffryar S, Akiri G, Neufeld G (2008) Semaphorin-3B is an angiogenesis inhibitor that is inactivated by furin like pro-protein convertases. Cancer research, 68, 6922-6931.
Kigel B, Varshavsky A, Kessler O, Neufeld, G (2008) Successful inhibition of tumor development by specific class-3 semaphorins is associated with expression of appropriate semaphorin receptors by tumor cells. PlosOne, 3, e3287.
Gutmann-Raviv N, Shraga-Heled N, Varshavsky A, Guimaraes-Sternberg C, Kessler O, Neufeld G (2007) Semaphorin-3A and semaphorin-3F work together to repel endothelial cells and to inhibit their survival by induction of apoptosis. J. Biol. Chem., 282, 26294-26305.
Neufeld G, Lange T, Varshavsky A, Kessler O (2006) Semaphorin signaling in vascular and tumor biology. Adv. Exp. Med. Biol. 600, 118-131.
The following ratings and reviews are based on verified feedback collected from independently administered patient experience surveys. The ratings and comments submitted by patients reflect their own views and opinions. Patient identities are withheld to ensure confidentiality and privacy. Learn more about our Patient Experience Ratings.
Patient comments